AGC Biologics Acquires Cell and Gene Therapy Commercial Manufacturing Facility

Published on: 

AGC Biologics has acquired Novartis’ Longmont, Colorado, manufacturing facility for the commercial production of cell and gene therapies.

AGC Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO), announced on Aug. 5, 2021 that it has finalized the acquisition of a commercial manufacturing facility in Longmont, Colo., previously owned by Novartis Gene Therapies. The facility significantly expands AGC Biologics’ capacity for producing cell and gene therapies, with additional space to expand.

The 622,000-ft2 facility is located 16 miles away from AGC Biologics’ large-scale stainless-steel mammalian facility in Boulder, Colo., and is expected to begin full-scale operations by the fourth quarter of 2021. Not only does the acquisition allow AGC Biologics to expand its cell and gene therapy footprint to the United States, it also enables the CDMO to continue rapidly expanding its process development and good manufacturing practice capacity for both early and late clinical/commercial demand.

AGC Biologics also announced major cell and gene therapy facility expansion projects at its Heidelberg, Germany, and Milan, Italy facilities in 2020 and 2021, respectively.


“The Longmont facility is just one of the company-wide expansion initiatives that AGC Biologics has been working on,” said Patricio Massera, CEO, AGC Biologics, in a company press release. “With our ongoing global expansion, we look forward to continuing to help our partners bring life-saving treatments to the market.”

Source: AGC Biologics